<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2019-642-646</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2799</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Роль прокальцитонинового теста в диагностике инфекций при иммуновоспалительных ревматических заболеваниях</article-title><trans-title-group xml:lang="en"><trans-title>The role of the procalcitonin test in the diagnosis of infections in immune-mediated inflammatory rheumatic diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муравьева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Muravyeva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Валерьевна Муравьева</p><p>Москва, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Natalia Muravyeva</p><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><email xlink:type="simple">n-muravjeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белов</surname><given-names>Б. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Belov</surname><given-names>B. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасова</surname><given-names>Г. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasova</surname><given-names>G. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2019</year></pub-date><volume>57</volume><issue>6</issue><fpage>642</fpage><lpage>646</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Муравьева Н.В., Белов Б.С., Тарасова Г.М., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Муравьева Н.В., Белов Б.С., Тарасова Г.М.</copyright-holder><copyright-holder xml:lang="en">Muravyeva N.V., Belov B.S., Tarasova G.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2799">https://rsp.mediar-press.net/rsp/article/view/2799</self-uri><abstract><p>Цель исследования — оценить роль прокальцитонинового теста в диагностике инфекций при иммуновоспалительных ревматических заболеваниях (ИВРЗ).</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 325 больных различными ИВРЗ: 216 женщин, 109 мужчин в возрасте от 2 до 82 лет. Концентрацию прокальцитонина (ПКТ) в сыворотке крови определяли количественным электрохемилюминесцентным методом на анализаторе Cobas E 411 (Roshe, Швейцария).</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Инфекционный процесс выявлен у 145 (44,6%) больных: генерализованный — у 11, локальный — у 134. В 61 случае локальные инфекции расценивались как тяжелые, в 73 — как легкие. У пациентов с генерализованной инфекцией медиана (Ме) уровня ПКТ составила 3,6 [0,88; 11,3] нг/мл. У 73% больных этой группы значения ПКТ превысили 2 нг/мл, у 27% — 10 нг/мл. При тяжелой локальной инфекции медиана содержания ПКТ составила 0,33 [0,23; 0,88] нг/мл, при легкой — 0,12 [0,05; 0,16] нг/мл. У больных без инфекции (n=180) она составила 0,11 [0,05; 0,17] нг/мл, при этом более высокие значения уровня ПКТ выявлены при болезни Стилла взрослых — 0,39 [0,14; 0,51] нг/мл, системной форме ювенильного артрита — 0,17 [0,11; 0,56] нг/мл исистемной красной волчанке — 0,11 [0,06; 0,15] нг/мл. При генерализованной инфекции уровень ПКТ был значимо выше, чем у пациентов без инфекции (p&lt;0,0001), а также с легкой (p&lt;0,0001) и тяжелой (p&lt;0,0001) локальной инфекцией. У больных с тяжелой локальной инфекцией уровень ПКТ был выше по сравнению с пациентами без инфекции (p&lt;0,001) и с легкой локальной инфекцией (p=0,004). Достоверных различий ПКТ в группах больных с легкой локальной инфекцией и без инфекции не выявлено. По данным ROC-анализа, диагностическая значимость определения ПКТ при генерализованной инфекции отличная, при тяжелой локальной инфекции — очень хорошая, при дифференциации генерализованной инфекции от локальной — очень хорошая.</p></sec><sec><title>Заключение</title><p>Заключение. Определение ПКТ, несомненно, способствует диагностике генерализованных и тяжелых локальных инфекций у больных ИВРЗ. Однако при интерпретации значений ПКТ следует учитывать совокупность данных: конкретную ревматическую нозологию, результаты клинико-лабораторного и инструментального обследований. Перспективным направлением в диагностике инфекций при ИВРЗ можно считать мультимаркерный подход.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to evaluate the role of the procalcitonin (PC) test in the diagnosis of infections in immune-mediated inflammatory rheumatic diseases (IIRDs).</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. The investigation enrolled 325 patients (216 women, 109 men) aged 2 to 82 years with different IIRDs. The serum PC concentration was determined by the quantitative electrochemiluminescence method using a Cobas E 411 analyzer (Roche, Switzerland).</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The infectious process was detected in 145 (44.6%) patients: generalized and local infections in 11 and 134 cases, respectively. Local infections were regarded as severe and mild in 61 and 73 cases, respectively. In patients with generalized infection, the median (Me) PC level was 3.6 [0.88; 11.3] ng/ml. In this group, the PC values exceeded 2 and 10 ng/ml in 73% and 27%, respectively. In severe local infection, the Me PC level was 0.33 [0.23; 0.88] ng/ml, in mild infection — 0.12 [0.05; 0.16] ng/ml. In 180 patients without infection, it was 0.11 [0.05; 0.17] ng/ml, whereas higher PC levels were found in adult onset Still's disease (0.39 [0.14; 0.51] ng/ml), systemic juvenile arthritis (0.17 [0.11; 0.56] ng/ml) and systemic lupus erythematosus (0.11 [0.06; 0.15] ng/ml). The level of PC was significantly higher in the patients with generalized infection than that in those without infection (p&lt;0.0001), as well as in those with mild (p&lt;0.0001) and severe (p&lt;0.0001) local infection. The PC level was higher in patients with severe local infection than in those without infection (p&lt;0.001) and in those with mild local infection (p=0.004). There were no significant differences in PC levels in the patients with mild local infection and in those without infection. The ROC analysis showed that the diagnostic significance of PC determination was excellent in generalized infection, very good in severe local infection, and very good when differentiating generalized from local infection.</p></sec><sec><title>Conclusion</title><p>Conclusion. Measuring PC is sure to contribute to the diagnosis of generalized and severe local infections in patients with IIRDs. However, when interpreting the PC values, it is necessary to take into account the pooled data: a specific rheumatic nosological entity and clinical, laboratory, and instrumental findings. The multimarker approach can be considered as a promising way to diagnose infections in IIRDs.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>иммуновоспалительные ревматические заболевания</kwd><kwd>инфекции</kwd><kwd>прокальцитониновый тест</kwd></kwd-group><kwd-group xml:lang="en"><kwd>immune-mediated inflammatory rheumatic diseases</kwd><kwd>infections</kwd><kwd>procalcitonin test</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53-61. doi: 10.1093/rheuma-tology/kes305</mixed-citation><mixed-citation xml:lang="en">Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53-61. doi: 10.1093/rheuma-tology/kes305</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101-36. doi: 10.1136/annrheumdis-2016-210708</mixed-citation><mixed-citation xml:lang="en">Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101-36. doi: 10.1136/annrheumdis-2016-210708</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ehrenstein B. [Acute exacerbation of the underlying disease or infection: Which diagnostics are warranted in patients with immunosuppressive treatment for inflammatory rheumatic diseases?]. ZRheumatol. 2019 Sep 11. doi: 10.1007/s00393-019-00705-1</mixed-citation><mixed-citation xml:lang="en">Ehrenstein B. [Acute exacerbation of the underlying disease or infection: Which diagnostics are warranted in patients with immunosuppressive treatment for inflammatory rheumatic diseases?]. ZRheumatol. 2019 Sep 11. doi: 10.1007/s00393-019-00705-1</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ромашева МЛ, Прошин ДГ. Диагностика сепсиса у больных в критических состояниях. Общая реаниматология. 2007;3(4):34-6</mixed-citation><mixed-citation xml:lang="en">Romasheva ML, Proshin DG. Diagnosis of sepsis in critically ill patients. Obshchaya Reanimatologiya. 2007;3(4):34-6 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Chiappa V, Briel V, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171(15):1322-31. doi: 10.1001/archinternmed.2011.318</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Chiappa V, Briel V, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171(15):1322-31. doi: 10.1001/archinternmed.2011.318</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shaikh MM, Hermans LE, van Laar JM. Is serum procalcitonin measurement a useful addition to a rheumatologist's repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology (Oxford). 2015;54(2):231-40. doi: 10.1093/rheumatology/keu416</mixed-citation><mixed-citation xml:lang="en">Shaikh MM, Hermans LE, van Laar JM. Is serum procalcitonin measurement a useful addition to a rheumatologist's repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology (Oxford). 2015;54(2):231-40. doi: 10.1093/rheumatology/keu416</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Meisner M. Procalcitonin — biochemistry and clinical diagnosis. Bremen: UNI-MED; 2010. 128 p.</mixed-citation><mixed-citation xml:lang="en">Meisner M. Procalcitonin — biochemistry and clinical diagnosis. Bremen: UNI-MED; 2010. 128 p.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Белов БС, Тарасова ГМ, Муравьева НВ. Роль биомаркеров в диагностике бактериальных инфекций при ревматических заболеваниях. Научно-практическая ревматология. 2019;57(3):333-8 doi: 10.14412/1995-4484-2019-333-338</mixed-citation><mixed-citation xml:lang="en">Belov BS, Tarasova GM, Muravyeva NV. Role of biomarkers in the diagnosis of bacterial infections in rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):333-8 (In Russ.). doi: 10.14412/1995-4484-2019-333-338</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Вельков ВВ. Прокальцитонин и С-реактивный белок в современной лабораторной диагностике. Клинико-лабораторный консилиум. 2008;25(6):46-52</mixed-citation><mixed-citation xml:lang="en">Vel'kov VV. Procalcitonin and C-reactive protein in modern laboratory diagnostics. Kliniko-Laboratornyy Konsilium = Clinical Laboratory Council of Physicians. 2008;25(6):46-52 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wu J-Y, Shen C-J, Hsieh Y-C, et al. Use of serum procalcitonin to direct bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(9):3034-42. doi: 10.1002/art.34512</mixed-citation><mixed-citation xml:lang="en">Wu J-Y, Shen C-J, Hsieh Y-C, et al. Use of serum procalcitonin to direct bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(9):3034-42. doi: 10.1002/art.34512</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Scire CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123-8.</mixed-citation><mixed-citation xml:lang="en">Scire CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123-8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chen DY, Chen YM, Ho WL, et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and noninfection inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis. 2009;68(6):1074-5. doi: 10.1136/ard.2008.098335</mixed-citation><mixed-citation xml:lang="en">Chen DY, Chen YM, Ho WL, et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and noninfection inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis. 2009;68(6):1074-5. doi: 10.1136/ard.2008.098335</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Чомахидзе АМ, Алексеева ЕИ. Прокальцитониновый тест в дифференциальной диагностике синдрома аллергосепсиса. Вопросы современной педиатрии. 2007;6(2):42-7</mixed-citation><mixed-citation xml:lang="en">Chomakhidze AM, Alekseeva EI. Procalcitonin test in the differential diagnosis of allergic sepsis syndrome. Voprosy Sovremennoy Pediatrii. 2007;6(2):42-7 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ho W-L, Lan J-L, Chen D-Y, et al. Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formosan J Rheumatol. 2009;23:52-8. doi: 10.1007/s10067-015-3020-0</mixed-citation><mixed-citation xml:lang="en">Ho W-L, Lan J-L, Chen D-Y, et al. Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formosan J Rheumatol. 2009;23:52-8. doi: 10.1007/s10067-015-3020-0</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Shin KC, Lee YJ, Kang SW, et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis. 2001;60(10):988-9. doi: 10.1136/ard.60.10.988</mixed-citation><mixed-citation xml:lang="en">Shin KC, Lee YJ, Kang SW, et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis. 2001;60(10):988-9. doi: 10.1136/ard.60.10.988</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schwenger V, Sis J, Breitbart A, et al. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998;26(5):274-6. doi: 10.1007/BF02962246</mixed-citation><mixed-citation xml:lang="en">Schwenger V, Sis J, Breitbart A, et al. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998;26(5):274-6. doi: 10.1007/BF02962246</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wallbach M, Vasko R, Hoffmann S, et al. Elevated procalcitonin levels in a severe lupus flare without infection. Lupus. 2016;25(14):1625-6. doi: 10.1177/0961203316651746</mixed-citation><mixed-citation xml:lang="en">Wallbach M, Vasko R, Hoffmann S, et al. Elevated procalcitonin levels in a severe lupus flare without infection. Lupus. 2016;25(14):1625-6. doi: 10.1177/0961203316651746</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">El-Serougy E, Zayed HS, Ibrahim NM, Maged LA. Procalcitonin and C-reactive protein as markers of infection in systemic lupus erythematosus: the controversy continues. Lupus. 2019;28(11):1329-36. doi: 10.1177/096120331877710</mixed-citation><mixed-citation xml:lang="en">El-Serougy E, Zayed HS, Ibrahim NM, Maged LA. Procalcitonin and C-reactive protein as markers of infection in systemic lupus erythematosus: the controversy continues. Lupus. 2019;28(11):1329-36. doi: 10.1177/096120331877710</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Лапин СВ, Маслянский АЛ, Лазарева НМ и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. 2013;(1):28-33</mixed-citation><mixed-citation xml:lang="en">Lapin SV, Maslyanskiy AL, Lazareva NM, et al. The value of quantitative analysis of procalcitonin in diagnostics of septic complications in patients with systemic autoimmune diseases. Klinicheskaya Laboratornaya Diagnostika. 2013;(1):28-33 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Serio I, Arnaud L, Mathian A, et al. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol. 2014;33(9):1209-15. doi: 10.1007/s10067-014-2738-4</mixed-citation><mixed-citation xml:lang="en">Serio I, Arnaud L, Mathian A, et al. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol. 2014;33(9):1209-15. doi: 10.1007/s10067-014-2738-4</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lanoix JP, Bourgeois AM, Schmidt J, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus. 2011;20(2):125-30. doi: 10.1177/0961203310378862</mixed-citation><mixed-citation xml:lang="en">Lanoix JP, Bourgeois AM, Schmidt J, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus. 2011;20(2):125-30. doi: 10.1177/0961203310378862</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ospina FE, Echeverri A, Zambrano D, et al. Distinguishing infections vs flares in patients with systemic lupus erythematosus. Rheumatology. 2017;56(Suppl 1):i46-i54. doi: 10.1093/rheumatol-ogy/kew340</mixed-citation><mixed-citation xml:lang="en">Ospina FE, Echeverri A, Zambrano D, et al. Distinguishing infections vs flares in patients with systemic lupus erythematosus. Rheumatology. 2017;56(Suppl 1):i46-i54. doi: 10.1093/rheumatol-ogy/kew340</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
